Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Deferred Taxes: 2016-2020

  • Summit Therapeutics' Deferred Taxes fell 182.50% to -$99,000 in Q4 2020 from the same period last year, while for Dec 2020 it was -$32.7 million, marking a year-over-year change of. This contributed to the annual value of -$1.9 million for FY2019, which is N/A change from last year.
  • As of Q4 2020, Summit Therapeutics' Deferred Taxes stood at -$99,000, which was down 182.50% from $120,000 recorded in Q4 2019.
  • Summit Therapeutics' 5-year Deferred Taxes high stood at $120,000 for Q4 2019, and its period low was -$32.7 million during Q4 2016.
  • For the 2-year period, Summit Therapeutics' Deferred Taxes averaged around $10,500, with its median value being $10,500 (2019).
  • Data for Summit Therapeutics' Deferred Taxes shows a maximum YoY plummeted of 182.50% (in 2020) over the last 5 years.
  • Over the past 4 years, Summit Therapeutics' Deferred Taxes (Quarterly) stood at -$32.7 million in 2016, then reached -$29,311 in 2017, then reached $120,000 in 2019, then crashed by 182.50% to -$99,000 in 2020.
  • Its Deferred Taxes stands at -$99,000 for Q4 2020, versus $120,000 for Q4 2019 and -$29,311 for Q1 2017.